Overview

Terazosin for Dementia With Lewy Bodies

Status:
Not yet recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The TZ-DLB trial will be a 3:2 (active:placebo) randomized, double-blind, placebo-controlled Pilot trial to evaluate the tolerability of terazosin for the treatment of dementia with Lewy bodies.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Qiang Zhang

Treatments:

Prazosin
Terazosin